{"success":true,"data":{"pressRelease":{"id":"85235","rtpr_id":"nWkr578sQt","ticker":"CHOSA","exchange":"","all_tickers":["CHOSA"],"title":"CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP","author":"Cision","published_at":"2026-07-10T06:30:02.268Z","article_body":"Chosa Oncology AB\n10th  July 2026 - CHOSA Oncology AB (\"CHOSA\" or the \"Company\") today\nannounces the appointment of Bill Cronin to support the Company's commercial\nexpansion in the United States. Bill Cronin will lead CHOSA's US business\ndevelopment and commercialization activities as the Company advances the\nmarket introduction of Platin-DRP® in the world's largest oncology\ndiagnostics market. Bill Cronin will be based in Kendall Square, Boston the\nmost important oncology centre in the US.\n \n\nThe appointment follows CHOSA's recent clinical progress, including the\npresentation of data from the ETOP/EORTC SPLENDOUR study, where Platin-DRP®\nidentified patients with advanced lung cancer achieving a median overall\nsurvival of 16.9 months compared with 5.6 months for patients predicted not to\nbenefit from platinum therapy. These results further support CHOSA's US\ncommercialization strategy for Platin-DRP®.\n\nBill Cronin brings more than two decades of executive leadership and\ncommercial experience from the US life science, especially the oncology field\nand medical technology sectors. Most notably, he served as Chief Executive\nOfficer of Dignitana AB from 2015 to 2022, where he led the commercialization\nof the Company's FDA-cleared DigniCap® Scalp Cooling System, used together\nwith chemotherapy in breast cancer, in the United States. Under his\nleadership, Swedish Dignitana established its US commercial organization,\nexpanded adoption at leading cancer centres, and transformed the United States\ninto the Company's primary commercial market. Dignitana was acquired by the\nBritish company Paxman Coolers - a process where Bill was deeply involved.\n\nAt CHOSA, Bill Cronin will focus on executing the Company's US\ncommercialization strategy, including developing relationships with\npharmaceutical companies, academic cancer centres, clinical laboratories,\nstrategic partners, and key opinion leaders. He will also support the planned\nResearch Use Only (RUO) launch of Platin-DRP® and help position the Company\nfor future commercial expansion.\n\nIngrid Atteryd Heiman, Chairman of CHOSA Oncology, commented:\n\n\"Having worked closely with Bill for many years during the successful\nexpansion of Dignitana in the United States, I have first-hand experience of\nhis ability to transform innovative Scandinavian healthcare technologies into\ncommercially successful businesses in the US market. His leadership, strategic\nmindset, and extensive network will be invaluable assets as CHOSA enters its\nnext phase of growth. We are delighted to welcome Bill to the CHOSA team.\"\n\nPeter Buhl Jensen, CEO of CHOSA Oncology, added:\n\n\"The United States represents our most important commercial market, and Bill's\nunique experience in building US operations for a Swedish oncology company\naligns perfectly with CHOSA's strategy. His commercial expertise and\nunderstanding of the US oncology ecosystem will significantly strengthen our\nability to establish Platin-DRP® in the market.\"\n\nBill Cronin commented:\n\n\"Having helped bring a number of Scandinavian life science innovations to the\nUS market, I find Platin-DRP® one of the most exciting I've worked with yet.\nThe CHOSA team has built something that can genuinely change how oncologists\ndecide if platinum therapy is the right choice for their patients. I'm\ngrateful for the chance to help lead that effort, and I'm looking forward to\nworking alongside the really impressive team CHOSA has put together to get it\nthere.\"\n\nThe appointment follows CHOSA's recent establishment of its US presence in\nBoston and represents another important milestone in building the commercial\norganization needed to support the long-term growth and commercialization of\nPlatin-DRP® in the United States.\n\n \n\nFor more information please contact:\n\nPeter Buhl Jensen, CEO\n\npeter@chosa.bio\n+ 45 21 60 89 22\n \n\nAbout CHOSA Oncology AB\nCHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene\nexpression-based biomarker that predicts response to platinum-based\nchemotherapy. By identifying patients most likely to benefit, CHOSA aims to\nimprove outcomes and optimize treatment selection in cancer care.\n\nBackground\n\nCisplatin and its sister molecule carboplatin have been cornerstones in lung\ncancer therapy for decades. Despite advances in immunotherapy, platinum drugs\nremain critical in treatment regimens, including combinations with PD-1/L1\ninhibitors. While numerous efforts to predict cisplatin efficacy have failed,\nthe Platin-DRP, based on a 205-gene biomarker signature, has shown promising\nresults in other settings, including adjuvant therapy in NSCLC and\nprogression-free survival in breast cancer.\n\nAs previously announced, CHOSA is also exploring the predictive potential of\nPlatin-DRP in those treated with carboplatin in lung cancer. Data from the\nSPLENDOUR trial provides a unique opportunity to validate this tool in a large\ncohort and potentially confirm its utility across both drugs. Future research\nwill also aim to determine whether Platin-DRP can predict the effectiveness of\nplatinum drugs combined with PD-1/L1 inhibitors. CHOSA Oncology AB is an\noncology biotechnology company led by an experienced international team with\nexpertise in oncology, drug development, clinical trials, regulatory affairs,\nand business development. CHOSA intends to enter into partnership or\nsublicensing agreements for LiPlaCis® and the DRP®.\n\nAbout Platin-DRP, a test to predict if cisplatin treatment is likely to be\nsuccessful\n\nCHOSA is focused on its Platin-DRP® drug response predictor, to which it\nholds worldwide rights. Platin-DRP is a validated test designed to help\nidentify patients most likely to benefit from cis- and carboplatin treatment.\nMost recently, CHOSA presented results from the ETOP/EORTC SPLENDOUR study\ndemonstrating that patients with advanced lung cancer predicted to benefit\nfrom platinum therapy achieved a median overall survival of 16.9 months\ncompared with 5.6 months for patients predicted not to benefit.\n\nBreast: Strong phase 2b data in metastatic breast cancer have shown that\npatients selected by DRP® responded better to treatment, had longer\nprogression-free survival, and may also have achieved longer overall survival\nthan patients identified as unlikely to respond well.\n\nLung: Platin-DRP has also demonstrated its ability to predict the benefit of\nadjuvant cisplatin in lung cancer. Cisplatin treatment after surgery remains a\ngold standard that can improve cure rates, but doctors have not had a\nvalidated tool to identify which patients are most likely to benefit. This is\nwhere Platin-DRP may become a game changer, particularly in newer neoadjuvant\nsettings where immunotherapy has shown high efficacy in combination with\nplatinum doublets. Platin-DRP was validated in a blinded retrospective study\nin two lung cancer patient cohorts receiving cisplatin after surgery to\neliminate residual tumour cells. Patients with the 10% highest scores had a\n3-year survival of 90%, whereas patients with the lowest 10% scores had a\n3-year survival of only 40%¹. In 2026 CHOSA in collaboration with key opinion\nleaders in lung cancer showed the Platin-DRP in advanced clearly separated the\npatient with a sensitive cancer from a platin resistant tumor with a median\nsurvival of 16.9 months in the former group vs only 5.5 months in the latter2.\n \n\nImmunotherapy Cisplatin and carboplatin have often been shown to activate the\nimmune system, potentially making \"cold\" tumours more susceptible to PD-1\ninhibitors. This synergy may be important not only in lung cancer, but also in\nbreast cancer, bladder cancer and head & neck cancer. In the growing PD-1\ninhibitor market, CHOSA's approach may offer the ability to predict whether\nplatin can provide synergy with PD-1 inhibition, potentially creating a\nmeaningful advantage for treatment selection and future partners.\n\n \n\n1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609 2) ESMO Open Volume\n11, Supplement 3, 106773, April 2026\n\nDRP® is a registered trademark of Allarity Therapeutics, Inc., and is used\nunder license granted to CHOSA. LiPlaCis is in-licensed from Allarity\nTherapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.\n\nhttps://news.cision.com/chosa-oncology-ab/r/chosa-oncology-appoints-us-commercialization-bill-cronin-with-a-broad-network-in-the-oncology-market%2Cc4373385\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr578sQt","title":"CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP","author":"Cision","ticker":"CHOSA","created":"2026-07-10T06:30:02.268Z","tickers":["CHOSA"],"exchange":"","article_body":"Chosa Oncology AB\n10th  July 2026 - CHOSA Oncology AB (\"CHOSA\" or the \"Company\") today\nannounces the appointment of Bill Cronin to support the Company's commercial\nexpansion in the United States. Bill Cronin will lead CHOSA's US business\ndevelopment and commercialization activities as the Company advances the\nmarket introduction of Platin-DRP® in the world's largest oncology\ndiagnostics market. Bill Cronin will be based in Kendall Square, Boston the\nmost important oncology centre in the US.\n \n\nThe appointment follows CHOSA's recent clinical progress, including the\npresentation of data from the ETOP/EORTC SPLENDOUR study, where Platin-DRP®\nidentified patients with advanced lung cancer achieving a median overall\nsurvival of 16.9 months compared with 5.6 months for patients predicted not to\nbenefit from platinum therapy. These results further support CHOSA's US\ncommercialization strategy for Platin-DRP®.\n\nBill Cronin brings more than two decades of executive leadership and\ncommercial experience from the US life science, especially the oncology field\nand medical technology sectors. Most notably, he served as Chief Executive\nOfficer of Dignitana AB from 2015 to 2022, where he led the commercialization\nof the Company's FDA-cleared DigniCap® Scalp Cooling System, used together\nwith chemotherapy in breast cancer, in the United States. Under his\nleadership, Swedish Dignitana established its US commercial organization,\nexpanded adoption at leading cancer centres, and transformed the United States\ninto the Company's primary commercial market. Dignitana was acquired by the\nBritish company Paxman Coolers - a process where Bill was deeply involved.\n\nAt CHOSA, Bill Cronin will focus on executing the Company's US\ncommercialization strategy, including developing relationships with\npharmaceutical companies, academic cancer centres, clinical laboratories,\nstrategic partners, and key opinion leaders. He will also support the planned\nResearch Use Only (RUO) launch of Platin-DRP® and help position the Company\nfor future commercial expansion.\n\nIngrid Atteryd Heiman, Chairman of CHOSA Oncology, commented:\n\n\"Having worked closely with Bill for many years during the successful\nexpansion of Dignitana in the United States, I have first-hand experience of\nhis ability to transform innovative Scandinavian healthcare technologies into\ncommercially successful businesses in the US market. His leadership, strategic\nmindset, and extensive network will be invaluable assets as CHOSA enters its\nnext phase of growth. We are delighted to welcome Bill to the CHOSA team.\"\n\nPeter Buhl Jensen, CEO of CHOSA Oncology, added:\n\n\"The United States represents our most important commercial market, and Bill's\nunique experience in building US operations for a Swedish oncology company\naligns perfectly with CHOSA's strategy. His commercial expertise and\nunderstanding of the US oncology ecosystem will significantly strengthen our\nability to establish Platin-DRP® in the market.\"\n\nBill Cronin commented:\n\n\"Having helped bring a number of Scandinavian life science innovations to the\nUS market, I find Platin-DRP® one of the most exciting I've worked with yet.\nThe CHOSA team has built something that can genuinely change how oncologists\ndecide if platinum therapy is the right choice for their patients. I'm\ngrateful for the chance to help lead that effort, and I'm looking forward to\nworking alongside the really impressive team CHOSA has put together to get it\nthere.\"\n\nThe appointment follows CHOSA's recent establishment of its US presence in\nBoston and represents another important milestone in building the commercial\norganization needed to support the long-term growth and commercialization of\nPlatin-DRP® in the United States.\n\n \n\nFor more information please contact:\n\nPeter Buhl Jensen, CEO\n\npeter@chosa.bio\n+ 45 21 60 89 22\n \n\nAbout CHOSA Oncology AB\nCHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene\nexpression-based biomarker that predicts response to platinum-based\nchemotherapy. By identifying patients most likely to benefit, CHOSA aims to\nimprove outcomes and optimize treatment selection in cancer care.\n\nBackground\n\nCisplatin and its sister molecule carboplatin have been cornerstones in lung\ncancer therapy for decades. Despite advances in immunotherapy, platinum drugs\nremain critical in treatment regimens, including combinations with PD-1/L1\ninhibitors. While numerous efforts to predict cisplatin efficacy have failed,\nthe Platin-DRP, based on a 205-gene biomarker signature, has shown promising\nresults in other settings, including adjuvant therapy in NSCLC and\nprogression-free survival in breast cancer.\n\nAs previously announced, CHOSA is also exploring the predictive potential of\nPlatin-DRP in those treated with carboplatin in lung cancer. Data from the\nSPLENDOUR trial provides a unique opportunity to validate this tool in a large\ncohort and potentially confirm its utility across both drugs. Future research\nwill also aim to determine whether Platin-DRP can predict the effectiveness of\nplatinum drugs combined with PD-1/L1 inhibitors. CHOSA Oncology AB is an\noncology biotechnology company led by an experienced international team with\nexpertise in oncology, drug development, clinical trials, regulatory affairs,\nand business development. CHOSA intends to enter into partnership or\nsublicensing agreements for LiPlaCis® and the DRP®.\n\nAbout Platin-DRP, a test to predict if cisplatin treatment is likely to be\nsuccessful\n\nCHOSA is focused on its Platin-DRP® drug response predictor, to which it\nholds worldwide rights. Platin-DRP is a validated test designed to help\nidentify patients most likely to benefit from cis- and carboplatin treatment.\nMost recently, CHOSA presented results from the ETOP/EORTC SPLENDOUR study\ndemonstrating that patients with advanced lung cancer predicted to benefit\nfrom platinum therapy achieved a median overall survival of 16.9 months\ncompared with 5.6 months for patients predicted not to benefit.\n\nBreast: Strong phase 2b data in metastatic breast cancer have shown that\npatients selected by DRP® responded better to treatment, had longer\nprogression-free survival, and may also have achieved longer overall survival\nthan patients identified as unlikely to respond well.\n\nLung: Platin-DRP has also demonstrated its ability to predict the benefit of\nadjuvant cisplatin in lung cancer. Cisplatin treatment after surgery remains a\ngold standard that can improve cure rates, but doctors have not had a\nvalidated tool to identify which patients are most likely to benefit. This is\nwhere Platin-DRP may become a game changer, particularly in newer neoadjuvant\nsettings where immunotherapy has shown high efficacy in combination with\nplatinum doublets. Platin-DRP was validated in a blinded retrospective study\nin two lung cancer patient cohorts receiving cisplatin after surgery to\neliminate residual tumour cells. Patients with the 10% highest scores had a\n3-year survival of 90%, whereas patients with the lowest 10% scores had a\n3-year survival of only 40%¹. In 2026 CHOSA in collaboration with key opinion\nleaders in lung cancer showed the Platin-DRP in advanced clearly separated the\npatient with a sensitive cancer from a platin resistant tumor with a median\nsurvival of 16.9 months in the former group vs only 5.5 months in the latter2.\n \n\nImmunotherapy Cisplatin and carboplatin have often been shown to activate the\nimmune system, potentially making \"cold\" tumours more susceptible to PD-1\ninhibitors. This synergy may be important not only in lung cancer, but also in\nbreast cancer, bladder cancer and head & neck cancer. In the growing PD-1\ninhibitor market, CHOSA's approach may offer the ability to predict whether\nplatin can provide synergy with PD-1 inhibition, potentially creating a\nmeaningful advantage for treatment selection and future partners.\n\n \n\n1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609 2) ESMO Open Volume\n11, Supplement 3, 106773, April 2026\n\nDRP® is a registered trademark of Allarity Therapeutics, Inc., and is used\nunder license granted to CHOSA. LiPlaCis is in-licensed from Allarity\nTherapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.\n\nhttps://news.cision.com/chosa-oncology-ab/r/chosa-oncology-appoints-us-commercialization-bill-cronin-with-a-broad-network-in-the-oncology-market%2Cc4373385\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-07-10T06:30:02.368588117Z","server_sent_at_ms":1783665002368},"received_at":"2026-07-10T06:30:02.426Z","source_url":"https://news.cision.com/chosa-oncology-ab/r/chosa-oncology-appoints-us-commercialization-bill-cronin-with-a-broad-network-in-the-oncology-market%2Cc4373385"},"analysis":{"id":"74294","press_release_id":"85235","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"CHOSA Oncology appointed Bill Cronin to lead its US business development and commercialization efforts from Boston, aiming to accelerate the launch of its Platin-DRP diagnostic.\n\nThe appointment follows clinical data where Platin-DRP identified advanced lung cancer patients with a median overall survival of 16.9 months versus 5.6 months for predicted non-beneficiaries.\n\nCronin brings experience from Dignitana and will focus on the RUO launch of Platin-DRP and building partnerships with pharma companies and cancer centers.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Strategic hire signals next step in US commercialization plans."},"keyFigures":{"drugName":"Platin-DRP®","customDimensions":{"3_year_survival_low_score":"40%","3_year_survival_high_score":"90%","median_survival_months_benefit":16.9,"median_survival_months_no_benefit":5.6}},"quotedText":"I find Platin-DRP® one of the most exciting I've worked with yet.","namedEntities":{"people":[{"name":"Bill Cronin","role":"US commercialization lead"},{"name":"Ingrid Atteryd Heiman","role":"Chairman"},{"name":"Peter Buhl Jensen","role":"CEO"}],"products":["Platin-DRP®","DigniCap® Scalp Cooling System","LiPlaCis®"],"companies":[{"name":"Dignitana AB","relationship":"previous employer of Bill Cronin"},{"name":"Paxman Coolers","relationship":"acquirer of Dignitana"},{"name":"Allarity Therapeutics, Inc.","relationship":"trademark licensor"},{"name":"Allarity Therapeutics Ltd","relationship":"licensor"},{"name":"LiPlasome Pharma ApS","relationship":"licensor"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Appointment of an experienced commercial leader is a positive operational step for US expansion, but executive hires (non-CEO/CFO) are typically not market-moving events for small-cap biotechs."},"tickerRelevance":{"others":[],"primary":"CHOSA"},"globalImportance":10,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"executive_hire","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"CHOSA Oncology appointed Bill Cronin to lead its US business development and commercialization efforts from Boston, aiming to accelerate the launch of its Platin-DRP diagnostic.\n\nThe appointment follows clinical data where Platin-DRP identified advanced lung cancer patients with a median overall survival of 16.9 months versus 5.6 months for predicted non-beneficiaries.\n\nCronin brings experience from Dignitana and will focus on the RUO launch of Platin-DRP and building partnerships with pharma companies and cancer centers.","key_figures":{"drugName":"Platin-DRP®","customDimensions":{"3_year_survival_low_score":"40%","3_year_survival_high_score":"90%","median_survival_months_benefit":16.9,"median_survival_months_no_benefit":5.6}},"named_entities":{"people":[{"name":"Bill Cronin","role":"US commercialization lead"},{"name":"Ingrid Atteryd Heiman","role":"Chairman"},{"name":"Peter Buhl Jensen","role":"CEO"}],"products":["Platin-DRP®","DigniCap® Scalp Cooling System","LiPlaCis®"],"companies":[{"name":"Dignitana AB","relationship":"previous employer of Bill Cronin"},{"name":"Paxman Coolers","relationship":"acquirer of Dignitana"},{"name":"Allarity Therapeutics, Inc.","relationship":"trademark licensor"},{"name":"Allarity Therapeutics Ltd","relationship":"licensor"},{"name":"LiPlasome Pharma ApS","relationship":"licensor"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-10T07:42:03.751Z","global_importance":10,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"executive_hire","sectorWeight":"biotech"}},"durationMs":684720,"modelName":"george-droid-qwen-72b"}}